392P - Solitary extramedullary plasmacytoma (SEMP) of head and neck: An individual patient data meta-analysis of 315 patients

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Plasma Cell Dyscrasias
Presenter Bhanu Venkatesulu
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors B.P. Venkatesulu1, S. Mallick2, A.G.F. Thoyattan1, G.K. Rath1
  • 1Radiation Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2Radiotherapy, All India Institute of Medical Sciences, 110029 - Delhi/IN



SEMP is a rare localized plasma cell neoplasm. We intended to perform this review of published literature to assess the demographic profile, pattern of care and assess survival outcomes


Two authors (BP and SM) independently searched PubMed, google search, and Cochrane library for eligible studies from 1950 till July 1 2016 published in English language.


Median age of the cohort was 57 years(Range 11-85).Gender predisposition skewed in favor of males 71.3% and females 28.7%.Site wise distribution were Paranasal sinuses 22.3%, nasal cavity 17.5%, nasopharynx10.8%, larynx 18.2%, Oral cavity 2.2%, oropharynx 12.1%, hypopharynx 0.6%, thyroid 3.5%, salivary Glands 3.5%, nodal mass 2.9%, orbit 6.4%, others1.3%. Sino nasal 50.6% and non-Sino nasal 49.4% distribution. Bony erosion was seen in 9.52% of the patients. Median size of SEMP 3 cm (Range 0.3-12 cm) .19.36% patients had SEMP size RT alone> Surgery on univariate analysis. Risk factors for myeloma relapse were coexisting diseases, site of disease (Sino nasal), bony erosion, size of lesion >5 cm and type of treatment received.


Our study shows that combined modality S+RT is superior compared to unimodality in preventing local recurrence. Radiation dose of 45 Gy is optimal. Nodal irradiation had no impact on local recurrence

Clinical trial indentification

Legal entity responsible for the study

Bhanu Prasad venkatesulu


All India Institute of Medical Sciences


All authors have declared no conflicts of interest.